The Cancer Center will evaluate a new expansion technology.
PerkinElmer’s ViaCord Research Institute™ (VRI) and The University of Texas M.D. Anderson Cancer Center have extended their collaboration related to advancing technologies that multiply cord blood stem cells.
M.D. Anderson is conducting a clinical trial to explore a cord blood expansion technology called Co-culture. The trial seeks to determine whether its use will be safe and result in more rapid engraftment in adults receiving cord blood transplants.
Co-culture is being designed to increase the total number of stem cells available from a single cord blood unit, since often the quantity of stem cells available from one umbilical cord blood unit is not sufficient to treat adult patients.
Based on the results of this trial, ViaCord and M.D. Anderson will determine the feasibility of using unrestricted somatic stem cells derived from cord blood in the co-culture of cord blood units for transplantation.